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Introduction
Chronic lymphocytic leukemia (CLL), which is the most
frequent form of leukemia in Western countries, predomi-
nantly affects the elderly.1,2 Chemoimmunotherapy is consid-
ered the standard therapy for CLL.3,4 Unfortunately, most eld-
erly patients do not tolerate intensive therapy, thus leaving
them without effective treatment.5 In this context, new
agents which target specific CLL pathogenic pathways (e.g.,
BCR-signal inhibitors) and have a good safety profile could
represent important progress in the treatment of CLL in the
elderly.6–8 A better understanding of the disease characteristics
and prognostic factors in elderly patients is also important for
improving the outcome of this group.
Here we report the clinico-biological characteristics of a
large, single-institution series of subjects with CLL according
to age-groups and focus on the outcomes and prognosis of
elderly subjects (≥70 years) with CLL.
Methods 
Patients and study design
In total, 949 patients diagnosed with CLL from January 1990 to
December 2012 at the Hospital Clínic of Barcelona were evaluated.
The study was approved by the local Institutional Review Board and
was performed in accordance with the Declaration of Helsinki. Four
groups of patients were distinguished: <59 years old (n=345), 60-69
years old (n=237), 70-79 years old (n=234) and ≥80 years old (n=133).
Data collected at diagnosis included age, sex, functional status, Binet
and Rai stage, absolute lymphocyte count, immunoglobulin levels,
cytogenetic abnormalities determined by fluorescent in situ hybridiza-
tion (FISH), b2-microglobulin (B2M) and lactate dehydrogenase levels,
ZAP-70 and CD38 expression, IGHVmutational status and NOTCH1
and SF3B1 mutations, using previously described methods.9–11 Due to
the retrospective nature of the study not all variables were available
for all patients. 
Treatment modalities varied over the years. Renal function at diag-
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We investigated the clinico-biological features, outcomes, and prognosis of 949 patients with chronic lymphocytic
leukemia according to age. No biological differences (cytogenetics by fluorescent in situ hybridization, IGHV, ZAP-
70, CD38, NOTCH1, SF3B1) were found across age groups. Elderly patients (>70 years; n=367) presented more
frequently with advanced disease (Binet C/Rai III-IV: 10/12% versus 5/5%; P<0.001), were treated less frequently
(23.8% versus 41.9% at 3 years; P<0.001) and in most cases did not receive highly effective regimens and thus had
a lower overall response rate (49% with 14% having complete responses versus 69% with 31% having complete
responses; P<0.001). The elderly patients also had a shorter overall survival (6.6 versus 13.3 years; P<0.001) and
higher disease-unrelated mortality (34.9% versus 6.9% at 10 years; P<0.001). However, disease-attributable mor-
tality was not significantly different between younger and older patients. A combination of Binet stage, ZAP-70
level, b2-microglobulin concentration and comorbidity identified two risk groups (low-risk: 0-1 parameters; high-
risk: 2-4 parameters) with different overall survivals (median: 6.8 versus 11.4 years, P<0.001). In patients requiring
treatment, comorbidity at treatment (Cumulative Illness Rating Scale-T>4; hazard ratio 2.2, P<0.001) and response
(treatment failure versus response: hazard ratio 1.60, P<0.04) were the most important prognostic factors for overall
survival. In conclusion, in our series, elderly patients with chronic lymphocytic leukemia did not present with any
biological features distinct from those of younger patients, but did have a poorer clinical outcome. This study high-
lights the importance of comprehensive medical care, achieving response to therapy, and specific management
strategies for elderly patients with chronic lymphocytic leukemia.
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ABSTRACT
nosis was estimated by calculation of the creatinine clearance
using the Modification of Diet in Renal Disease (MDRD) formula.
For patients aged ≥70 years, the Cumulative Illness Rating Scale
(CIRS) was retrospectively assessed at the time of diagnosis (CIRS-
D) and first-line treatment (CIRS-T).12,13 The assessment of the
CIRS is detailed in the Online Supplementary Appendix. 
Statistical methods
Baseline characteristics of patients of different age groups were
compared using the χ2 or ANOVA test as appropriate. Cut-off lev-
els for CIRS-D and CIRS-T were determined using maximally
selected rank statistics. Time to first treatment was defined as time
from diagnosis to date of initiation of first treatment or last follow-
up. Overall survival was defined as the time between diagnosis
and the date of death or last follow-up using the Kaplan-Meier
method. Comparisons between different age groups and other
covariates were performed by means of the log-rank test. Relative
survival was calculated comparing the actuarial survival with that
of the Spanish population matched by age, sex and calendar year
of diagnosis. In patients aged 70 or older, multivariate analysis of
prognostic factors for time to first treatment, overall survival and
survival from first treatment was performed with Cox regression
models after multiple imputation of missing data.14 IGHV,
NOTCH1 and SF3B1 mutations were not included in the multi-
variate analysis because of the high number of missing data
(>50%).
To avoid a bias in favor of responders, the impact of response
on the overall survival was determined by a landmark analysis (9
months after treatment initiation).15 Unadjusted P-values <0.05
were considered statistically significant. Statistical methods are
detailed in the Online Supplementary Appendix.
Results
Patients’ characteristics
The median age at diagnosis of the whole series of 949
patients was 65 years (range, 28-97), with 367/949 (39%)
being 70 years of age or older. The median follow-up was
7.8 years. The main characteristics according to age groups
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Table 1. Characteristics of 949 patients with CLL according to age. 
< 59 years 60-69 years 70-79 years ≥ 80 years P
(n=345) (n=237) (n=234) (n=133)
Median age (years, range) 52 (28-59) 64 (60-69) 74 (70-79) 83 (80-97) -
Sex, male (%) 225 (65) 140 (59) 120 (51) 70 (53) 0.004
Performance Status > 1 (%) 5/320 (2) 5/223 (2) 10/222 (5) 25/119 (21) <0.001
Median creatinine clearance  (mL/min, range) 79 (34-116) 77 (44-120) 69 (19-120) 64 (26-120) <0.001
B symptoms (%) 21/305 (7) 8/214 (4) 14/222 (6) 10/129 (8) NS
Rai stage(%)
0 163/335 (48) 153/231 (66) 141/227 (62) 82/131 (63)
I/II 156/335 (47) 66/231 (29) 66/227 (29) 26/131 (19) <0.001
III/IV 16/335 (5) 12/231 (5) 20/227 (9) 23/131 (18)
Binet stage (%) 
A/B 319/335(95) 221/231(96) 210/227(93) 113/131(86) <0.001
C 16/335 (5) 10/231 (4) 17/227 (7) 18/131 (14)
White blood count x109/L 36.3± 51.8 26.7±30.3 27.1±40.8 26±30 0.01
Lymphocytes x109/L 26.7±40.7 19.2±25 20.1±37 18.9±25.9 0.03
Hemoglobin g/dL 13.9±1.7 13.7±1.8 13.3±1.7 12.6±2.1 <0.001
Platelet count x109/L  195±64 201±66 207±81 189±83 NS
Lactate dehydrogenase increased (%) 35/316 (11) 23/224(10) 28/223 (13) 20/124 (16) NS
B2M mg/L 2.34±1.53 2.51±1.35 3.24±1.99 3.78±1.94 <0.001
ZAP-70 ≥ 20% (%) 102/258 (40) 59/178 (33) 52/165 (32) 16/62 (26) NS
CD38 >30% (%) 79/144 (32) 52/161 (32) 43/152 (28) 18/53 (34) NS
IGHV unmutated (%) 118/231 (51) 56/144 (39) 51/117 (44) 17/40 (43) NS
NOTCH1mutated (%) 22/218 (10) 13/132 (10) 17/106(16) 5/45 (11) NS
SF3B1mutated (%) 19/191 (10) 8/110 (7) 5/83 (6) 3/28 (11) NS
FISH (number, %)
Del 13q het 80/252 (32) 67/175 (38) 61/157 (39) 24/57 (42)
Normal 69/252 (27) 57/175 (33) 45/157 (29) 17/57 (30)
Trisomy 12 35/252 (14) 23/175 (13) 24/157 (15) 5/57 (9) NS
Del 11q 39/252 (15) 17/175 (10) 16/157 (10) 7/57 (12)
Del 17p 29/252 (12) 11/175 (6) 11/157 (7) 4/57 (7)
Immunoglobulin levels decreased (%)
IgG 48/262 (18) 27/191 (14) 27/184 (15) 16/100 (16)
IgM 76/262 (29) 49/191 (26) 46/184 (25) 29/100 (29) NS
IgA 48/262 (18) 33/191 (17) 30/184 (16) 13/100 (13)
NS: not significant; IGHV (immunoglobulin heavy chain gene) unmutated: ≥ 98% identity with germline; FISH: fluorescence in situ hybridization.
are shown in Table 1. In summary, older patients (>70
years) presented with a poorer performance status, worse
renal function and a more advanced stage of disease than
did younger ones.
Treatment
The cumulative proportion of patients receiving therapy
was significantly lower for elderly patients [23.8% (19.5-
28.3%) versus 41.9% (37.7-46%) at 3 years and 42.7 (37.1-
48.3%) versus 63.3% (58.7-67.7%) at 10 years, P<0.001]. 
In the univariate analysis, parameters correlated with a
shorter time to first treatment were advanced clinical stage
(P<0.001), increased B2M (P<0.001), high-risk FISH cyto-
genetics as defined by the presence of 11q- or 17p deletion
(P<0.001), increased ZAP-70 (P<0.001), unmutated IGHV
(P<0.001), and NOTCH1 (P<0.001) and SF3B1 (P<0.001)
mutations. Patients with a CIRS higher than 6 (CIRS-D>6)
tended to have a longer time to first treatment (P=0.053).
In the multivariate analysis clinical stage, B2M, and ZAP-
70 retained prognostic significance (Table 2). 
Elderly patients were more likely to initially receive
alkylating agents (70% versus 36%) than purine analogs
(10% versus 32%) or chemoimmunotherapy (5% versus
25%) (P<0.001 for all comparisons) and their response to
therapy was lower (overall response rate 49% versus 69%;
P<0.001; complete response 14% versus 31%; P<0.001).
Moreover, a higher proportion of elderly patients failed to
benefit from therapy (24% versus 16%; P<0.001).
Overall survival  
The median overall survival was significantly shorter in
elderly patients (6.6 versus 13.3 years; P<0.001, Figure 1).
However, when adjusted for age, sex and year of diagno-
sis, CLL-attributable mortality was similar in both cohorts:
3.7% versus 5.2% at 3 years, and 28.8% versus 30.2% at 10
years. CLL-unrelated mortality was significantly higher in
elderly patients [12% (8.6-15.4%) versus 1.5% (.5-2.5%) at
3 years; 35% (29.5-40.5%) versus 7% (4.6-9.4%) at 10
years; P<0.001].
Variables associated with overall survival in elderly
patients are shown in Table 2 and Figure 2A-D. In this
cohort, beside standard prognostic variables, comorbidity
was also evaluated. The median comorbidity burden at
diagnosis (CIRS-D) was 5 (range, 0-17). Elderly patients
with a CIRS-D >6 tended to have a shorter overall survival
(univariate analysis, P=0.064) (Figure 2D). The multivari-
ate analysis showed independent prognostic value for clin-
ical stage, B2M, ZAP-70, and comorbidity. High-risk FISH
cytogenetics did not enter into the prognostic model. 
Based on the results of the multivariate analysis we ten-
tatively designed a prognostic model including clinical
stage (Binet A versus B/C), B2M (<2.3 mg/dL versus ≥2.3
mg/dL), ZAP-70 (<20% versus ≥20%), and comorbidity
(CIRS-D ≤6 versus >6). This model identified two prognos-
tic groups with significantly different survival [low risk (0-
1 parameters), median overall survival 11.4 years versus
high risk (2-4 parameters), median overall survival 6.8
years; P<0.001] (Figure 3).
Finally, we evaluated the prognosis of patients aged ≥70
years requiring treatment using a landmark analysis
(n=115). To this end we reassessed CIRS at treatment
(CIRS-T) which was comparable to that at diagnosis
(median CIRS-D: 5; range, 0-17; median CIRS-T: 5; range,
0-15). There was a correlation between the overall
CLL in the elderly
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Table 2. Hazard ratios and 95% confidence intervals for overall survival, time to first treatment and overall survival from first treatment according
to clinico-biological features in patients with CLL aged 70 years or older.
Overall survival Time to first treatment Overall survival from
first treatment
Univariate Multivariate Univariate Multivariate Univariate Multivariate
Log-rank Cox regression Log-rank Cox regression Log-rank Cox regression
P HR P P HR P P HR P
(95% CI) (95% CI) (95% CI)
Binet stage 0.001 1.68 0.012 <0.001 3.95 <0.001 NS - -
(1.12-2.52) (2.54-6.17)
B2M > 2.3 mg/L 0.001 1.09 0.021 <0.001 2.97 <0.001 NS - -
(1.01-1.16) (1.94-4.55)
High risk FISH 0.016 - NS <0.001 NS NS NS - -
(del11q, del17p)
ZAP-70 0.001 1.64 0.01 <0.001 2.20 <0.001 NS - -
(1.13-2.4) (1.56-3.09)
IGHVmutation status 0.002 NE NE <0.001 NE NE NS - -
NOTCH1mutation status0.002 NE NE <.001 NE NE NS - -
SF3B1mutation status 0.001 NE NE <.001 NE NE NS - -
CIRS-D 0.064 1.42 0.035 .053 NS NS - - -
(1.02-1.97)
CIRS-T - - - - - - 0.012 2.21 0.001
(1.38-3.54)
Response to first treatment
Failure vs. 0.101 1.62 0.044
CR+PR (1.01-2.6)
HR: hazard ratio; CI: confidence interval; NS: not significant; PR: partial response; CR: complete response.
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Figure 1. Overall survival of the (A) whole series (median 9.7 years), and (B) according to age groups (<70 vs. ≥70 years) in patients with CLL
(median 6.6 vs. 13.3 years; P<0.001).
Figure 2. Estimates of overall survival since diagnosis for patients with CLL >70 years based on (A) Binet clinical stage (A, B, C) (median 7.2
vs. 4.9 vs. 2.1 years; P<0.001), (B) serum levels of b2-microglobulin (B2M) (median 10.2 vs. 6.2 years; P<0.001), (C) ZAP-70 expression (medi-
an 9.4 vs. 7.7 years; P<0.001), and (D) co-morbidity assessed by CIRS at diagnosis (CIRS-D) (median 7.7 vs. 6.7 years; P=0.064). Univariate
analysis was performed using the Kaplan-Meier method and log-rank test; P<0.05. 
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response rate and CIRS-T (45% for patients with CIRS-T
>4 versus 55% for patients with CIRS-T ≤4; P=0.049). The
univariate analysis revealed a significant correlation
between overall survival and comorbidity at treatment
(CIRS-T >4; P=0.012) while there was a tendency
towards a correlation between response to treatment and
overall survival (P<0.101). In the univariate analysis, clin-
ical stage and other variables such as B2M, high-risk FISH
cytogenetics, ZAP-70, CD38, mutational status of IGHV
and NOTCH1 and SF3B1 mutations did not show signif-
icant correlations with survival after therapy. In adjusted
analysis, only response to therapy and comorbidity
showed independent prognostic value for overall survival
(CIRS-T >4; hazard ratio 2.21; P=0.001 and treatment fail-
ure versus response to treatment; hazard ratio 1.62;
P=0.044) (Table 2).
Discussion
The definition of elderly subjects is arbitrary and, as a
result of the increasing life-expectancy of the general pop-
ulation, submitted to continuous revision. In our study, we
defined elderly CLL patients as those ≥70 years of age, a
cut-off that separated patients with marked differences in
overall survival. Patients ≥70 years of age accounted for
39% of the series, a proportion which has been main-
tained constant over the years (data not shown). This per-
centage is similar to that found in other studies16 but small-
er than that reported by the SEER (54%),1 which most
likely reflects differences between data from academic
centers and population-based data. While the well-known
male predominance in patients with CLL was corroborat-
ed in the overall series (58%), it was not observed in sub-
jects ≥70 years of age (52%). The reasons for this disparity
could include differences in life expectancy (longer in
women) and differences in access to medical care. In those
patients for whom information was available, biological
parameters such as ZAP-70, CD38, FISH cytogenetics, and
IGHV mutational status or NOTCH1 and SF3B1 muta-
tions (Table 1) were not differently distributed across age
groups. Not surprisingly, elderly CLL patients presented
with a poorer performance status and worse renal func-
tion than younger ones, which limits treatment with
intensive regimens.
There are few studies investigating the prognostic
impact of comorbidity in CLL.17–19 In a pooled analysis
comprising 555  patients comorbidity had an independent
impact on overall survival (71.7 versus 90.2 months;
P<0.001) due to higher therapy-related, CLL-unrelated,
and, particularly, CLL-related deaths.19 In the present study
we assessed comorbidity by CIRS12,13 at diagnosis (CIRS-
D) and prior to first treatment (CIRS-T). No correlation
was found between comorbidity and performance status,
which is in agreement with other studies.13 However, we
detected a relationship between overall response rate and
comorbidity at time of treatment (CIRS-T), which is in
line with other studies.18,19 A moderate to severe comor-
bidity burden (CIRS-D >6 and CIRS-T >4)  was strongly
associated with shorter overall survival. Of note, the cut-
off that better correlated with overall survival (CIRS-T >4)
was different from that in other studies.20 This indicates
that the significant comorbidity index regarding prognosis
can vary depending on the population and emphasizes the
need to standardize comorbidity assessment in patients
with CLL.
Clinical stage, B2M level and ZAP-70 expression were
identified as predictors for time to first treatment while
other parameters significant in univariate analysis, includ-
ing FISH cytogenetics, did not retain prognostic signifi-
cance. In agreement with other reports,16,21 elderly patients
were treated less frequently than younger ones. There are
various potential reasons for this, including less aggressive
disease21 and a more, not pre-determined conservative
approach to the management of older subjects. Also, most
elderly patients were given no effective therapies, which
resulted in a lower overall response rate. Although age by
itself has been associated with a lower response rate,3,4,22–24
the small number of elderly patients treated with fludara-
bine-based therapy (15%) precludes a meaningful analysis
of treatment effectiveness according to age. As shown by
others,16,25,26 biomarkers were not correlated with response.
This is not surprising because predictive biomarkers have
been mainly identified in younger patients treated with
effective therapies.3,4 It should not, however, be concluded
that predictive markers are unnecessary in elderly sub-
jects. On the contrary, predictive markers need to be stud-
ied prospectively, as done in recent studies.20,27 One point
to be taken into account is that, because of the differences
in the mechanisms of action of antileukemic drugs, predic-
tive markers for patients treated with new agents could be
different from those identified for patients treated with
fludarabine-based therapy. 
The advent of new agents (e.g., ibrutinib and idelalisib)
and monoclonal antibodies (e.g., obinutuzumab) for CLL
therapy is likely to change treatment paradigms in this
form of leukemia, particularly in elderly subjects.6–8,20,28,29
Several trials investigating treatment with oral kinase
inhibitors as single agents6,8 and in combination regi-
mens7,28 have shown that these drugs can provide long-
lasting disease control. Moreover, new monoclonal anti-
CLL in the elderly
haematologica | 2014; 99(10) 1603
Figure 3. Two different prognostic groups (low vs. high risk with median
survivals of 11.4 vs. 6.8 years; P<0.001) of elderly patients with CLL
based on four parameters of independent prognostic value for overall
survival by multivariate analysis (advanced Binet clinical stage,
increased levels of B2M, high expression of ZAP-70 and CIRS-D >6).
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bodies in combination with chlorambucil produced a sub-
stantial proportion of deep responses with an acceptable
safety profile.20,29 Further clinical trials in well stratified
patients are warranted. To that end, we devised a prognos-
tic model comprising information on clinical stage, comor-
bidity, B2M, and ZAP-70 which discriminated elderly
patients with CLL into two risk groups with significant
differences in survival (Figure 3). This prognostic model
should be validated in other independent series and the
relative merits of different biomarkers elucidated.30
Furthermore, the possibility that new compounds over-
come or mitigate the negative influence of some parame-
ters should be taken into account, and outcome predictors
refined based upon the discovery of biomarkers and pro-
gresses in treatment.
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